Neuphoria Therapeutics (B1N0) Stock Statistics & Valuation Metrics
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of EUR 14.73M. The enterprise value is EUR 3.89T.
- Market Cap
- EUR 14.73M
- Enterprise Value
- EUR 3.89T
Share Statistics
Neuphoria Therapeutics has 5,411,334 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,411,334
- Owned by Insiders
- ―
- Owned by Institutions
- 38.61%
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is -0.00 and return on invested capital (ROIC) is -0.03%.
- Return on Equity (ROE)
- -0.00
- Return on Assets (ROA)
- -0.00
- Return on Invested Capital (ROIC)
- -0.03%
- Return on Capital Employed (ROCE)
- -0.00
- Revenue Per Employee
- 1.17M
- Profits Per Employee
- -13.45M
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is -0.42. Neuphoria Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.42
- PS Ratio
- 14.06
- PB Ratio
- 0.67
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 1.17M and earned -13.45M in profits. Earnings per share was -3.06.
- Revenue
- 1.17M
- Gross Profit
- 511.21K
- Operating Income
- -9.81M
- Pretax Income
- -13.59M
- Net Income
- -13.45M
- EBITDA
- -9.15M
- Earnings Per Share (EPS)
- -3.06
Cash Flow
In the last 12 months, operating cash flow was -12.35B and capital expenditures 0, giving a free cash flow of -12.35B billion.
- Operating Cash Flow
- -12.35B
- Free Cash Flow
- -12.35B
- Free Cash Flow per Share
- -2282.91
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -74849.63%
- Earnings Yield
- -112.29%
Stock Price Statistics
- Beta
- 1.59
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 1.61
- 200-Day Moving Average
- 1.61
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Neuphoria Therapeutics upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Sep 29, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Neuphoria Therapeutics as a current ratio of 27.85, with Debt / Equity ratio of 0.00%
- Current Ratio
- 27.85
- Quick Ratio
- 27.85
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2171.68
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -139.17K in taxes.
- Income Tax
- -139.17K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is 0.26, with an EV/FCF ratio of 0.00.
- EV to Sales
- -2.83
- EV to EBITDA
- 0.26
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Neuphoria Therapeutics has EUR 19.87M in cash and marketable securities with EUR 34.34K in debt, giving a net cash position of EUR 19.83M billion.
- Cash & Marketable Securities
- EUR 19.87M
- Total Debt
- EUR 34.34K
- Net Cash
- EUR 19.83M
- Net Cash Per Share
- EUR 3.66
- Tangible Book Value Per Share
- EUR 3.13
Margins
Gross margin is 43.54%, with operating margin of -1187.73%, and net profit margin of -1578.40%.
- Gross Margin
- 43.54%
- Operating Margin
- -1187.73%
- Pretax Margin
- -1591.77%
- Net Profit Margin
- -1578.40%
- EBITDA Margin
- -1084.70%
- EBIT Margin
- -1141.17%